Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus: A Randomized Trial

吡格列酮 医学 糖尿病前期 内科学 非酒精性脂肪肝 胃肠病学 人口 安慰剂 糖尿病 2型糖尿病 2型糖尿病 脂肪肝 内分泌学 疾病 病理 替代医学 环境卫生
作者
Kenneth J. Cusi,Beverly Orsak,Fernando Bril,Romina Lomonaco,Joan Hecht,Carolina Ortiz‐Lopez,Fermin O. Tio,Jean Hardies,Celia Darland,Nicolas Musi,Amy Webb,Paola Portillo-Sánchez
出处
期刊:Annals of Internal Medicine [American College of Physicians]
卷期号:165 (5): 305-315 被引量:1076
标识
DOI:10.7326/m15-1774
摘要

BACKGROUND: The metabolic defects of nonalcoholic steatohepatitis (NASH) and prediabetes or type 2 diabetes mellitus (T2DM) seem to be specifically targeted by pioglitazone. However, information about its long-term use in this population is limited. OBJECTIVE: To determine the efficacy and safety of long-term pioglitazone treatment in patients with NASH and prediabetes or T2DM. DESIGN: Randomized, double-blind, placebo-controlled trial. (ClinicalTrials.gov: NCT00994682). SETTING: University hospital. PARTICIPANTS: Patients (n = 101) with prediabetes or T2DM and biopsy-proven NASH were recruited from the general population and outpatient clinics. INTERVENTION: All patients were prescribed a hypocaloric diet (500-kcal/d deficit from weight-maintaining caloric intake) and then randomly assigned to pioglitazone, 45 mg/d, or placebo for 18 months, followed by an 18-month open-label phase with pioglitazone treatment. MEASUREMENTS: The primary outcome was a reduction of at least 2 points in the nonalcoholic fatty liver disease activity score in 2 histologic categories without worsening of fibrosis. Secondary outcomes included other histologic outcomes, hepatic triglyceride content measured by magnetic resonance and proton spectroscopy, and metabolic parameters. RESULTS: Among patients randomly assigned to pioglitazone, 58% achieved the primary outcome (treatment difference, 41 percentage points [95% CI, 23 to 59 percentage points]) and 51% had resolution of NASH (treatment difference, 32 percentage points [CI, 13 to 51 percentage points]) (P < 0.001 for each). Pioglitazone treatment also was associated with improvement in individual histologic scores, including the fibrosis score (treatment difference, -0.5 [CI, -0.9 to 0.0]; P = 0.039); reduced hepatic triglyceride content from 19% to 7% (treatment difference, -7 percentage points [CI, -10 to -4 percentage points]; P < 0.001); and improved adipose tissue, hepatic, and muscle insulin sensitivity (P < 0.001 vs. placebo for all). All 18-month metabolic and histologic improvements persisted over 36 months of therapy. The overall rate of adverse events did not differ between groups, although weight gain was greater with pioglitazone (2.5 kg vs. placebo). LIMITATION: Single-center study. CONCLUSION: Long-term pioglitazone treatment is safe and effective in patients with prediabetes or T2DM and NASH. PRIMARY FUNDING SOURCE: Burroughs Wellcome Fund and American Diabetes Association.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
传奇3的应助被温屿采纳,获得10
1秒前
1秒前
王俊凯完成签到,获得积分10
1秒前
1秒前
fff完成签到 ,获得积分10
2秒前
2秒前
星辰坠于海的应助被元谷雪采纳,获得10
2秒前
科研通AI6.2的应助被Aleah_采纳,获得10
3秒前
青柳安发布了新的文献求助10
3秒前
nnniu完成签到 ,获得积分10
3秒前
4秒前
苦苦的曙光完成签到,获得积分10
4秒前
4秒前
5秒前
yuyu完成签到,获得积分10
5秒前
5秒前
康康完成签到,获得积分10
5秒前
5秒前
ZZZ发布了新的文献求助10
5秒前
酷波er的应助被林柒采纳,获得10
5秒前
朱琳发布了新的文献求助10
5秒前
iris完成签到,获得积分10
5秒前
爆米花的应助被大白兔采纳,获得10
6秒前
6秒前
李李李李李完成签到,获得积分10
6秒前
6秒前
Krstal发布了新的文献求助10
6秒前
heyou完成签到 ,获得积分10
6秒前
顺心夜南发布了新的文献求助10
6秒前
7秒前
李健的应助被光亮友安采纳,获得10
7秒前
bububuuu完成签到,获得积分10
7秒前
hy完成签到 ,获得积分10
7秒前
8秒前
MILA完成签到,获得积分10
8秒前
nb完成签到,获得积分10
8秒前
8秒前
一手灵魂完成签到,获得积分10
8秒前
伶俐耳机完成签到 ,获得积分10
8秒前
8秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
Analyses de reconnaissances de dettes passées devant les échevins d'Ypres (1249-1291) 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8159581
求助须知:如何正确求助?哪些是违规求助? 9555100
关于积分的说明 21724719
捐赠科研通 7749543
什么是DOI,文献DOI怎么找? 3427281
关于科研通互助平台的介绍 2552278
邀请新用户注册赠送积分活动 2471619